Skip to main
RAPT

RAPT Stock Forecast & Price Target

RAPT Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 56%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

RAPT Therapeutics is positioned for potential growth due to its promising pipeline, particularly related to the RPT904/JYB1904 programs, which may demonstrate differentiated efficacy in clinical trials slated for 2025. The company's RPT904 showcases a commercially validated mechanism of action with enhancements in half-life and pharmacokinetics, representing a de-risked opportunity in immunologic and asthmatic diseases. Additionally, the recent acquisition of Verona Pharma by Merck signals a growing interest within the pharmaceutical industry in immunology and inflammation therapeutics, further supporting RAPT's strategic positioning in the market.

Bears say

RAPT Therapeutics faces significant operational and financial challenges that contribute to a negative outlook for its stock. Key risks include potential safety signals and efficacy issues arising from its clinical programs, which could undermine investor confidence if studies fail to achieve statistical significance. Additionally, the company has considerable financing needs, estimating a cash runway only until 2027, with approximately $1.1 billion required through 2040, raising concerns about its long-term viability amidst increasing competition and regulatory risks.

RAPT has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rapt Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rapt Therapeutics Inc (RAPT) Forecast

Analysts have given RAPT a Buy based on their latest research and market trends.

According to 9 analysts, RAPT has a Buy consensus rating as of Jan 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rapt Therapeutics Inc (RAPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.